Israel-listed cell therapy biotech Bonus Biogroup sets terms for $15 million US IPO
IPO Overview
Bonus Biogroup, a Phase 2 Israeli biotech developing cell therapies for bone regeneration and respiratory indications, announced terms for its IPO on Thursday. The company is currently listed on the Tel Aviv Stock Exchange under the symbol “BONS,” where the last reported trading price was NIS 0.41, equivalent to a price of $3.97 per ADS.
The Haifa, Israel-based company plans to raise $15 million by offering 3 million ADSs at a price range of $4 to $6.
The company’s two lead product candidates are BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage. BonoFill completed a Phase 2 trial in maxillofacial bone defects in the upper and lower jaw bones for sinus augmentation and void filling, and is currently in a Phase 2 trial in defects in long and short limb bones incapable of self-healing or untreatable by standard techniques, with interim results expected in early 2026. MesenCure completed a Phase 2 trial for pulmonary manifestations of COVID in severely ill patients in 2022, and in February received clearance for a Phase 3 trial. The company plans to initiate a trial of MesenCure in all-cause respiratory distress in late 2025.
Bonus Biogroup was founded in 1981. It plans to list on the Nasdaq under the symbol BONS. D. Boral Capital is the sole bookrunner on the deal.
About the Company
We are a clinical-stage biotechnology company focused on developing next-generation therapies. Our mission is to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products that address severe conditions with limited treatment options. By leveraging our deep expertise and advancements in tissue engineering and cell therapy, we are developing BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage, both of which, we believe, may address significant unmet clinical and market needs. Cell and cell-based therapies, in which therapeutic cells are combined with other modalities, such as scaffolds for tissue engineering, are categorized based on the cells’ origin. Autologous （or self-derived） treatments utilize the patient’s own cells, whereas allogeneic treatments employ cells from external healthy human donors. While autologous cell therapies, especially those harnessing the patient’s immune cells, are predominantly utilized in cancer treatment （immunotherapy）， autologous, non-immune cell therapies, mostly involving mesenchymal stomal cells （MSC） and induced pluripotent stem cells, are under extensive investigation for their potential to repair damaged tissue such as bone, cartilage, heart muscle, and more.
